Literature DB >> 22665218

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.

Y Boumber, H Kantarjian, J Jorgensen, S Wen, S Faderl, R Castoro, J Autry, G Garcia-Manero, G Borthakur, E Jabbour, Z Estrov, J Cortes, J-P Issa, F Ravandi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22665218      PMCID： PMC3981542          DOI： 10.1038/leu.2012.153

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

Review 1.  Acute myeloid leukemia.

Authors:  B Löwenberg; J R Downing; A Burnett
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

Review 2.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

Authors:  Francesco Buccisano; Luca Maurillo; Maria Ilaria Del Principe; Giovanni Del Poeta; Giuseppe Sconocchia; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

3.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Authors:  Amanda F Cashen; Gary J Schiller; Margaret R O'Donnell; John F DiPersio
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

4.  Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.

Authors:  J F San Miguel; M B Vidriales; C López-Berges; J Díaz-Mediavilla; N Gutiérrez; C Cañizo; F Ramos; M J Calmuntia; J J Pérez; M González; A Orfao
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

5.  RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.

Authors:  Yanis A Boumber; Yutaka Kondo; Xuqi Chen; Lanlan Shen; Vazganush Gharibyan; Kazuo Konishi; Elihu Estey; Hagop Kantarjian; Guillermo Garcia-Manero; Jean-Pierre J Issa
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  Quantitative DNA methylation predicts survival in adult acute myeloid leukemia.

Authors:  Lars Bullinger; Mathias Ehrich; Konstanze Döhner; Richard F Schlenk; Hartmut Döhner; Matthew R Nelson; Dirk van den Boom
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

8.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

9.  DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.

Authors:  Shuchi Agrawal; Matthias Unterberg; Steffen Koschmieder; Udo zur Stadt; Uta Brunnberg; Walter Verbeek; Thomas Büchner; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

10.  LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability.

Authors:  Marcos R H Estécio; Vazganush Gharibyan; Lanlan Shen; Ashraf E K Ibrahim; Ketan Doshi; Rong He; Jaroslav Jelinek; Allen S Yang; Pearlly S Yan; Tim H-M Huang; Eloiza H Tajara; Jean-Pierre J Issa
Journal:  PLoS One       Date:  2007-05-02       Impact factor: 3.240
View more
  20 in total

Review 1.  Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Authors:  Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio
Journal:  Blood       Date:  2016-06-27       Impact factor: 22.113

2.  Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.

Authors:  Lina Han; Jeffrey L Jorgensen; Chris Brooks; Ce Shi; Qi Zhang; Graciela M Nogueras González; Antonio Cavazos; Rongqing Pan; Hong Mu; Sa A Wang; Jin Zhou; Gheath Ai-Atrash; Stefan O Ciurea; Mike Rettig; John F DiPersio; Jorge Cortes; Xuelin Huang; Hagop M Kantarjian; Michael Andreeff; Farhad Ravandi; Marina Konopleva
Journal:  Clin Cancer Res       Date:  2017-01-17       Impact factor: 12.531

3.  Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.

Authors:  Meagan A Jacoby; Michael G Martin; Geoffrey L Uy; Peter Westervelt; John F Dipersio; Amanda Cashen; Keith Stockerl-Goldstein; Ravi Vij; Jingqin Luo; Teresa Reineck; Noel Bernabe; Camille N Abboud
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

4.  Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.

Authors:  Brittany Knick Ragon; Naval Daver; Guillermo Garcia-Manero; Farhad Ravandi; Jorge Cortes; Tapan Kadia; Betul Oran; Maro Ohanian; Alessandra Ferrajoli; Naveen Pemmaraju; Hagop M Kantarjian; Gautam Borthakur
Journal:  Am J Hematol       Date:  2017-06-09       Impact factor: 10.047

Review 5.  Acute myeloid leukemia in the elderly: therapeutic options and choice.

Authors:  Jonathan A Webster; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-06-02

6.  Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.

Authors:  Selina M Luger; Victoria X Wang; Jacob M Rowe; Mark R Litzow; Elisabeth Paietta; Rhett P Ketterling; Hillard Lazarus; Witold B Rybka; Michael D Craig; Judith Karp; Brenda W Cooper; Adel Z Makary; Lynne S Kaminer; Frederick R Appelbaum; Richard A Larson; Martin S Tallman
Journal:  Leuk Res       Date:  2021-10-28       Impact factor: 3.156

Review 7.  Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

8.  Update on optimal management of acute myeloid leukemia.

Authors:  Fuad El Rassi; Martha Arellano
Journal:  Clin Med Insights Oncol       Date:  2013-08-12

9.  Epigenetic synergy between decitabine and platinum derivatives.

Authors:  Taichun Qin; Jiali Si; Noël J-M Raynal; Xiaodan Wang; Vazganush Gharibyan; Saira Ahmed; Xin Hu; Chunlei Jin; Yue Lu; Jingmin Shu; Marcos Rh Estecio; Jaroslav Jelinek; Jean-Pierre J Issa
Journal:  Clin Epigenetics       Date:  2015-09-11       Impact factor: 6.551

Review 10.  Clinical Results of Hypomethylating Agents in AML Treatment.

Authors:  Marjan Cruijsen; Michael Lübbert; Pierre Wijermans; Gerwin Huls
Journal:  J Clin Med       Date:  2014-12-25       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.